Effectiveness of Automated Insulin Management Features of the MiniMed®640G Sensor-Augmented Insulin Pump.
Automated insulin management features of the MiniMed®640G sensor-augmented pump system include suspension in response to predicted low sensor glucose (SG) values ("suspend before low"), suspension in response to existing low SG values ("suspend on low"), and automatic restarting of basal insulin delivery upon SG recovery. The effectiveness of these features was evaluated using CareLink®software data.



Anonymized data from MiniMed 640G system users (n = 4818), MiniMed 530G system users (n = 39,219), and MiniMed Paradigm®Veo™ system users (n = 43,193) who voluntarily uploaded pump and sensor data were retrospectively analyzed. Comparisons were made between days in which system features were enabled at any time and those in which they were not. Comparisons were also made between pump suspension events for which insulin delivery was automatically or manually resumed and between glycemic parameters of users who switched from the MiniMed Paradigm Veo system to the MiniMed 640G system.



Days in which the MiniMed 640G "suspend before low" feature was enabled had lower percentages of SG readings ≤70 mg/dL (3.9 mmol/L) or ≥240 mg/dL (13.3 mmol/L) than days when it was not enabled (P < 0.001 for each). Users who switched from the MiniMed Paradigm Veo system to the MiniMed 640G system had fewer excursions below ≤70 mg/dL (P < 0.001) and ≥240 mg/dL (P < 0.001). SG values following automatically resumed pump suspension events recovered more rapidly and had a more stabilized endpoint than following manually resumed events.



Automated insulin management features of the MiniMed 640G system can reduce the frequency of both high and low SG values and help stabilize SG after resumption of insulin delivery.
1 Medtronic , Northridge, California.
Alex
A
Zhong
2 Diabetes Research Group, King's College London , London, United Kingdom .
Pratik
P
Choudhary
1 Medtronic , Northridge, California.
Chantal
C
McMahon
1 Medtronic , Northridge, California.
Pratik
P
Agrawal
1 Medtronic , Northridge, California.
John B
JB
Welsh
1 Medtronic , Northridge, California.
Toni L
TL
Cordero
1 Medtronic , Northridge, California.
Francine R
FR
Kaufman
D001786:Blood Glucose / Q000032:analysis*; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000627:therapeutic use*; D007332:Insulin Infusion Systems; D012189:Retrospective Studies; D016896:Treatment Outcome
D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
J Diabetes Sci Technol. 2011 Sep 01;5(5):1137-41
22027306
Pediatr Diabetes. 2008 Aug;9(4 Pt 2):360-6
18774996
Diabetes Technol Ther. 2012 Mar;14(3):205-9
22316089
Diabetes Technol Ther. 2011 Jul;13(7):695-8
21668344
Diabetes Ther. 2016 Mar;7(1):45-60
26886441
Diabetes Technol Ther. 2011 Nov;13(11):1129-34
21827318
Diabetes Technol Ther. 2015 May;17(5):316-9
25611577
Diabetes Metab Res Rev. 2016 Sep;32(6):623-33
26789012
Diabetes Technol Ther. 2016 May;18(5):288-91
26907513
Diabetes Care. 2015 Nov;38(11):e186-7
26316630
N Engl J Med. 2015 Nov 26;373(22):2129-2140
26379095
Diabetes Care. 2010 May;33(5):1013-7
20200307
Diabetes Care. 2015 Jul;38(7):1197-204
26049549
Diabetes Care. 2016 Jul;39(7):1168-74
26740634
Diabetes Care. 2011 Sep;34(9):2023-5
21868778
Diabetes Technol Ther. 2017 May;19(5):288-292
28221823